Sunovion Announces Positive Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Children with ADHD

World News: . []

Sunovion Pharmaceuticals Inc Sunovion today announced positive results of a pivotal Phase 3 study SEP360-305 evaluating the efficacy and safety of novel drug candidate dasotraline a dopamine and norepinephrine reupta...

More news and information about Sunovion Pharmaceuticals Inc.

Published By:

Business Wire: 16:00 GMT Friday 21st April 2017

Published: .

Search for other references to "sunovion" on SPi News

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us

Advertising on SPi News: Information For Advertisers